DOM-BUPROPION SR 150 MG
BUPROPION HYDROCHLORIDE : 150 MG · DIN 02317761 · DOMINION PHARMACAL
Health Canada status: CANCELLED PRE MARKET
What is DOM-BUPROPION SR?
DOM-BUPROPION SR 150 MG contains BUPROPION HYDROCHLORIDE : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02317761, held by DOMINION PHARMACAL, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as cancelled pre market, status dated 30-May-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DOM-BUPROPION SR used for?
Symptomatic relief of major depressive illness.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02317761 |
|---|---|
| Brand name | DOM-BUPROPION SR |
| Generic / active ingredient | BUPROPION HYDROCHLORIDE : 150 MG |
| Manufacturer | DOMINION PHARMACAL |
| Strength | 150 MG |
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06AX12 BUPROPION |
| AHFS class | 28:16.04.92 |
| Biosimilar | No |
| Health Canada status | CANCELLED PRE MARKET |
| Status date | 30-May-2025 |
How is it administered?
Maximum daily dose 300 mg; maximum single dose 150 mg. Avoid bedtime doses to minimize insomnia. Do not crush or chew tablets.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (standard room temperature 15-30°C typically applies to this class).
How is it supplied?
Not explicitly detailed in provided text (standard bottles/blisters implied by 'smallest number of tablets' warning).
Contraindications
Seizure disorders, bulimia/anorexia nervosa, abrupt alcohol/sedative withdrawal, use of other bupropion products, MAOIs, and thioridazine.
Warnings and precautions
Increased risk of seizures (dose-dependent), suicidal ideation/behaviour, hypertension, psychosis, and severe allergic reactions (anaphylaxis).
What can be used instead?
Other Canadian products sharing ATC code N06AX12 BUPROPION. 9 of 32 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ODAN BUPROPION SR | 100 MG | TABLET (EXTENDED-RELEASE) | ODAN LABORATORIES LTD | MARKETED | DIN 02275074 |
| ODAN BUPROPION SR | 150 MG | TABLET (EXTENDED-RELEASE) | ODAN LABORATORIES LTD | MARKETED | DIN 02275082 |
| TARO-BUPROPION XL | 150 MG | TABLET (EXTENDED-RELEASE) | SUN PHARMA CANADA INC | MARKETED | DIN 02475804 |
| TARO-BUPROPION XL | 300 MG | TABLET (EXTENDED-RELEASE) | SUN PHARMA CANADA INC | MARKETED | DIN 02475812 |
| TEVA-BUPROPION XL | 150 MG | TABLET (EXTENDED-RELEASE) | TEVA CANADA LIMITED | MARKETED | DIN 02439654 |
| TEVA-BUPROPION XL | 300 MG | TABLET (EXTENDED-RELEASE) | TEVA CANADA LIMITED | MARKETED | DIN 02439662 |
| WELLBUTRIN XL | 150 MG | TABLET (EXTENDED-RELEASE) | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02275090 |
| WELLBUTRIN XL | 300 MG | TABLET (EXTENDED-RELEASE) | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02275104 |
| ZYBAN | 150 MG | TABLET (EXTENDED-RELEASE) | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02238441 |
| AVA-BUPROPION SR | 100 MG | TABLET (EXTENDED-RELEASE) | AVANSTRA INC | CANCELLED POST MARKET | DIN 02363399 |
Who else supplies BUPROPION worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BUPROPION appears in 114 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.